Lack Of Diversity In Clinical Trials Presents Possible Health Consequences
By Rae Ellen Bichell,
National Public Radio
| 12. 17. 2015
Untitled Document
Despite striking ethnic disparities in the incidence and mortality of diseases like cancer and respiratory disease, minorities are not well represented in clinical trials. A paper out in the journal PLOS Medicine says two main barriers to achieving diverse clinical trials are the expense of recruiting minority subjects, and fears of exploitation in medical research.
ARI SHAPIRO, HOST:
About 40 percent of Americans belong to a racial or ethnic minority. But the people who participate in clinical trials are much more homogeneous. These trials are the studies that test whether drugs work and inform doctors' decisions about how to treat their patients. As NPR's Rae Ellen Bichell reports, that mismatch can have big health consequences.
RAE ELLEN BICHELL, BYLINE: Here's the gist of an article this week in the journal PLOS Medicine - clinical trials in biomedical research are too white.
SAM OH: Yeesh (laughter) it's a little jarring to hear it that way.
BICHELL: But that's the reality. Sam Oh is an epidemiologist at UC San Francisco. He was one of a group of 14 researchers who...
Related Articles
By Margaret R. Eby, Los Angeles Review of Books | 03.15.2026
IN MARCH 2017, then–vice president Mike Pence tweeted a photo of himself at a table with members of the House Freedom Caucus discussing plans to repeal the Affordable Care Act (ACA) and replace it with the American Health Care Act...
By Michael Levenson, The New York Times | 02.27.2026
The pharmaceutical giant Novartis has reached a settlement with the family of Henrietta Lacks, a Black woman whose cells were taken from her without her consent in 1951, when she was dying of cervical cancer in a segregated ward at...
By Tania Fabo, Truthout | 02.28.2026
The reproductive tech company Orchid recently launched a genetic test that promises a whole genome sequencing report for embryos. It is the first such test commercially available to couples undergoing in vitro fertilization (IVF) and claims to detect things like...
By Pete Shanks
| 02.27.2026
Last month, we published “The Shameful Legacy of Tuskegee” which focused on a proposed experiment in Guinea-Bissau. The study’s plan echoed the notorious Tuskegee disaster, withholding safe, effective vaccines against hepatitis B from some newborns while inoculating others. It was to be financed by the U.S. but performed by a controversial Danish team. That project provoked a multi-national outcry, leading to a remarkable response from the World Health Organization:
WHO has significant concerns regarding the study’s scientific...
